TCL Archive Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies. April 30, 2004
TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive Fountain Hearings Turn Up Some Responsible Criticism, some Not, Much Support for Program June 24, 1977
